3 results match your criteria: "Department of Medicine Yale School of Medicine New Haven CT USA.[Affiliation]"
Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.
J Am Heart Assoc
July 2023
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine Beth Israel Deaconess Medical Center Boston MA USA.
Article Synopsis
- This study examined the impact of frailty on outcomes in older patients (≥65 years) undergoing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention, using Medicare claims data to define frailty.
- Results showed that frail patients had a significantly higher rate of adverse clinical events (23.1%) compared to nonfrail patients (10.7%) at 18 months follow-up.
- While there were no notable differences in the effects of standard versus extended duration DAPT on outcomes for frail versus nonfrail patients, further research is needed to explore how frailty affects bleeding and ischemic risks with DAPT.
Drug-Coated Balloon and Drug-Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease.
J Am Heart Assoc
April 2023
Vascular Medicine Outcomes Program (VAMOS), Section of Cardiovascular Medicine, Department of Medicine Yale School of Medicine New Haven CT USA.
Background Patients with severe-stage chronic kidney disease (CKD) were excluded from femoropopliteal disease trials evaluating drug-coated balloons (DCBs) and drug-eluting stents (DESs) versus plain balloon angioplasty (POBA) and bare metal stents (BMSs). We examined the interaction between CKD status and device type for the association with 24-month all-cause mortality and major amputation risk. Methods and Results We studied patients undergoing femoropopliteal interventions (September 2016-December 2018) from Medicare-linked VQI (Vascular Quality Initiative) registry data.
View Article and Find Full Text PDF